Friday, August 1, 2025

Latest

MindMed Starts Dosing Patients In Phase 1 Clinical Study On MDMA-Like Substances

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Tuesday that the first patient has been dosed in a Phase 1 investigator-initiated study aimed to evaluate the effects of MDMA-like substances. The study is being led by the firm’s collaborator and the program’s principal investigator, Dr. Matthias Liechti at University Hospital Basel.

The trial involves 24 healthy subjects who will randomly receive doses of MDMA or MDMA-like substances like MDA, Lys-MDMA, and Lys-MDA, while the rest will get placebo treatments. The study aims to assess the subjective effects of the various drugs for future application of the substance in treating disorders.

“By using pharmacokinetics and modern psychological and psychometric tests, this study will investigate the potential to better control the bioavailability, slow the effect onset and reduce possible adverse effects of MDMA and MDA by using these prodrugs,” said Dr. Liechti.

The principal investigator also said the study will investigate the “effects of MDA in direct comparison with MDMA for the first time in humans.”

Executive President Dr. Miri Halperin Wernli added that the study “will enhance our understanding of the therapeutic properties involved in the induction of positive mood in a way that may help optimize the treatment model for our R(-)-MDMA drug candidate.”

The firm started in October 2021 to develop R(-)-MDMA for treating symptoms related to autism spectrum disorder.

Mind Medicine Inc. last traded at $9.35 on the NEO.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why Gold’s Bull Run May Just Be Getting Started! | Peter Grandich

Tariffs Spark New Race for Critical Metals | Rob McEwen

Antimony Resources: The Bald Hill Project

Recommended

Tsunami Warnings Spread As Largest Quake Since 2011 Hits Russia

Northern Superior Intersects 1.75 g/t Gold Over 65.0 Metres At Philibert

Related News

Mind Medicine Closes The Year Out With Further Management Departures

Mind Medicine (NEO: MMED) has seen further management departures, following the departure of its CEO...

Wednesday, December 29, 2021, 08:38:09 AM

MindMed Begins Study On LSD Neutralizer Technology

MindMed (NEO: MMED) this morning announced that it has begun a study on what it...

Wednesday, February 17, 2021, 08:18:59 AM

Mind Medicine Sees Final Co-Founder Leave The Company

Mind Medicine (NEO: MMED) appears to now be fully under new management. On Friday evening,...

Sunday, January 9, 2022, 03:07:00 PM

Mindmed To Conduct 15-To-1 Reverse Split To Meet Nasdaq Listing Requirements

In a classic Canadian small cap move, Mind Medicine (NEO: MMED) last night announced that...

Friday, August 5, 2022, 08:42:02 AM

MindMed Declares US$17.0 Million Net Loss, US$105.7 Million Cash Balance For Q2 2022

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Thursday its financial...

Friday, August 12, 2022, 08:20:03 AM